2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3320 Blinatumomab with reduced-intensity vincristine and prednisone for induction of newly diagnosed adult B-cell acute lymphoblastic leukemia: A prospective single-arm cohort.

Jun Feng, Jian Li, MD2
1 Peking Union Medical College Hospital, Beijing, China
2 Peking Union Medical College Hospital, Beijing, China

Background:

B-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/LBL) remains a challenging disease in adults. Although multiagent chemotherapy induces complete remission (CR) in 85–90% of patients, regimens containing asparaginase or hyper-CVAD are associated with substantial toxicity and suboptimal minimal residual disease (MRD) negativity rates.

Methods:

This single-center, prospective, single-arm observational cohort study was conducted at Peking Union Medical College Hospital (Beijing, China). We enrolled consecutive adults (aged ≥14 years) who had newly diagnosed CD19-positive B-ALL. Patients received vincristine 4 mg on days 1, 8, 15, and 22; prednisone 60 mg/m² daily on days 1–14; and blinatumomab 9 µg/day on days 8–14 and 28 µg/day on days 15–21. Philadelphia chromosome-positive (Ph+) patients received olverembatinib 40 mg every other day. Primary endpoints were complete remission (CR) rate and MRD negativity by multicolor flow cytometry (MFC, sensitivity 10?4). Secondary endpoints included induction mortality, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and minimal residual disease assessed by PCR (quantitative PCR or droplet digital PCR; sensitivity 10?4).

Results:

Between January 2024 and July 2026, 39 patients were enrolled. The median age was 52 years (range, 14–75); 28% were aged ≥60 years. The cohort included 13 Ph+ patients (33%), of whom 11 had BCR-ABL1 p190 and 2 had p210 transcripts. Among the remaining 26  Philadelphia chromosome-negative (Ph−) patients, the spectrum of genetic abnormalities included ZNF384/362 fusions (n=5), MLL fusions (n=2), Ph-like (n=2), E2A-PBX1 (n=1), PAX5 P80R (n=1), other PAX5 fusions (n=1), and DUX4::IgH (n=1). Three patients had a history of prior non-hematologic malignancies treated with radiotherapy and/or chemotherapy, three patients had a history of cytopenia or myelodysplastic syndrome (MDS), and one patient had HIV infection.

Among the 37 patients evaluable for response (one died of fungal septic shock prior to assessment and another showed bone marrow necrosis on marrow examination), the CR rate was 94.6% (35/37). All 13 Ph+ patients achieved CR (100%; 95% CI, 75.3–100%), as did 22 of 24 Ph− patients (91.7%; 95% CI, 78.9–99.9%). One Ph− patient achieved partial remission (PR) and subsequently received salvage therapy, another Ph− patient who had achieved a PR subsequently attained complete remission (CR) after 7 days of continued blinatumomab therapy.

MFC-MRD negativity was achieved in 96.9% (31/32; 95% CI, 76.3–98.1%) of evaluable CR patients. By subgroup, this rate was 92.3% (12/13) among Ph+ patients and 100% (19/19) among Ph− patients. In the Ph+ subgroup, 4 (30.8%) achieved BCR/ABL negativity after induction therapy, and 6 (46.2%) achieved a molecular response with BCR/ABL levels below 10?4. In the Ph− subgroup, 9 of 10 patients (90%) achieved molecular MRD negativity, except for one patient with a residual PCR-MRD level of 0.023%.

CRS occurred in 26 of 39 patients (66.7%), with a median time to onset of 1 day (range, 1–14 days). Most cases were grade 1 (n=14, 53.8% of CRS events) or grade 2 (n=7, 26.9%); grade 3 CRS was observed in 5 patients, accounting for 12.8% of the total cohort. Tocilizumab was administered to 11 patients (28.2%). No grade 4–5 CRS or ICANS was observed. Tocilizumab was used in 11 patients (28.2%).

Induction-related mortality was 2.6% (1/39). This patient developed invasive pulmonary fungal infection with septic shock during neutropenia and died on day 17, before response assessment. The median duration of grade 4 neutropenia was 6.5 days (range, 0–35 days). The median duration of grade 4 thrombocytopenia (platelet count <20×10?/L) was 0 days (range, 0–14 days). Infectious complications included bacterial infections in 6 patients (15.4%), fungal infections in 2 patients (5.1%), and viral infections (COVID-19, influenza, or varicella-zoster) in 4 patients (10.3%).

Conclusions: A 2-week regimen of blinatumomab combined with reduced-intensity vincristine and prednisone achieved high rates of complete remission and deep MRD negativity by flow cytometry in newly diagnosed adult B-ALL patients regardless of Philadelphia chromosome status, with a particularly high molecular MRD negativity rate observed in the Ph− subgroup. The regimen was well tolerated, with a favorable safety profile and low hematologic toxicity.

Jun Feng: No relevant conflicts of interest to declare.